Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537584 · ClinicalTrials.gov registry record · Phase 4
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
A Phase 4 study of Major Depressive Disorder, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 133
- Enrollment target
- 1
- Study location
NCT05537584: Completed Phase 4 study of Major Depressive Disorder, sponsored by Mclean Hospital.
NCT05537584 is a Phase 4 study of Major Depressive Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 133 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05537584, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 133 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
Primary Outcome
Symptoms of depression
Conditions Studied
Interventions
- DRUG Sertraline
- DRUG Bupropion
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 4 |
What the finished NCT05537584 record still lists
NCT05537584 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sertraline is the first listed.
NCT05537584 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05537584 about?
NCT05537584 is a clinical study titled "SMART Trial to Predict Anhedonia Response to Antidepressant Treatment". The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
What is the current status of trial NCT05537584?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 133 participants. The study started on 2022-09-30. Estimated completion is 2025-08-26.
What conditions does trial NCT05537584 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05537584?
The interventions under investigation include: Sertraline (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT05537584?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537584 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05537584's enrollment target sits among peer trials
133 111th of 282 higher than 172 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI